帕罗西汀联合舒肝解郁胶囊在抑郁症患者中的应用价值探讨

The application value of Paroxetine combined with Shuganjieyu capsule in patients with depression

目的探讨帕罗西汀联合舒肝解郁胶囊在抑郁症患者中的应用价值。方法选取2022年9月-2023年9月在福州市精神病人疗养院接受帕罗西汀联合舒肝解郁胶囊用药治疗的23例抑郁症患者作为观察组,同期选取在该院接受帕罗西汀单独用药治疗的19例抑郁症患者作为对照组,对两组临床资料进行回顾性对比分析。结果经治疗,两组患者SCL-90各维度评分、PSQI、SF-36评分均得到显著改善(P<0.05),且治疗后观察组患者SCL-90各维度评分、PSQI、SF-36评分均显著优于对照组(P<0.05)。观察组患者不良反应发生率显著低于对照组(P<0.05)。结论对于抑郁症患者,在帕罗西汀治疗基础上加用舒肝解郁胶囊可显著提升治疗效果,减少患者不良反应,值得临床借鉴推广。

Objective To explore the clinical value of Paroxetine combined with Shuganjieyu capsule in the treatment of depression.Methods From September 2022 to September 2023,23 patients with depression treated with Paroxetine combined with Shuganjieyu capsule in our hospital were selected as observation group,at the same time,19 cases of depression treated by Paroxetine alone in our hospital were selected as control group,and the clinical data of the two groups were analyzed retrospectively.Results After treatment,the scores of SCL-90,PSQI and SF-36 were significantly improved in both groups(P<0.05),after treatment,the scores of SCL-90,PSQI and SF-36 in the observation group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion For the patients with depression,Shuganjieyu capsule on the basis of the treatment of Paroxetine can significantly improve the therapeutic effect and reduce the adverse reactions in patients,which is worthy of clinical promotion.